title: [Recommendations for use of rituximab in patients with rheumatoid arthritis].
abstract: Treatment with rituximab (RTX) has been approved since 2006 for patients with rheumatoid arthritis who previously failed to respond to tumor necrosis factor (TNF) inhibitor therapy or who experienced side effects. In these updated treatment recommendations new data relating to evaluation of the therapeutic response, retreatment, the role of predictive factors as well as safety data are incorporated and discussed.
authors.affiliation: Klinik I für Innere Medizin, Uniklinik Köln, Kerpener Str. 62, Haus 16, 1. OG, Raum 1.008, 50937, Köln, Deutschland, andrea.rubbert@uk-koeln.de.
authors.forename: A
authors.initials: A
authors.lastname: Rubbert-Roth
authors.forename: G R
authors.initials: GR
authors.lastname: Burmester
authors.forename: T
authors.initials: T
authors.lastname: Dörner
authors.forename: A
authors.initials: A
authors.lastname: Gause
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage* / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000008:administration & dosage; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005858:Germany; D006801:Humans; D017410:Practice Guidelines as Topic; D012219:Rheumatology / Q000592:standards*; D000069283:Rituximab; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab